Hims & Hers Health (NYSE:HIMS) Shares Gap Down – Time to Sell?

Posted by Brian Himes on Aug 11th, 2026

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report)’s share price gapped down prior to trading on Tuesday . The stock had previously closed at $31.77, but opened at $29.71. Hims & Hers Health shares last traded at $30.9070, with a volume of 6,076,303 shares changing hands.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Raised revenue outlook: Hims & Hers increased its 2026 revenue forecast to $3.1 billion-$3.3 billion from $2.8 billion-$3.0 billion. Third-quarter revenue guidance of $880 million-$900 million also exceeds the current consensus estimate. Hims & Hers Boosts Revenue Target, Swings to Second-Quarter Loss
Positive Sentiment: Solid growth drivers: Second-quarter revenue reached approximately $753.2 million, up 38.2% year over year and above analysts’ expectations. Subscriber growth, personalized healthcare offerings, AI-driven engagement and expansion of specialty care supported management’s optimistic outlook. Hims & Hers raises annual forecast revenue on strong subscriber growth
Positive Sentiment: Analyst support: Needham raised its price target for HIMS from $35 to $42 and maintained a Buy rating, citing potential upside from the company’s growth initiatives. Needham raises Hims & Hers price target
Neutral Sentiment: AI and international expansion: Management highlighted artificial intelligence, broader specialty-care services and Eucalyptus’s international reach as long-term growth opportunities, although these initiatives may require continued investment.
Negative Sentiment: Large earnings miss: Hims & Hers reported a second-quarter loss of $0.37 per share, versus expectations for a loss of about $0.05, reversing year-ago earnings of $0.17 per share. The loss was also wider than some data providers’ estimates. Hims & Hers Health Slides on Wider-Than-Expected Q2 Loss
Negative Sentiment: Margin pressure: Spending on branded GLP-1 weight-loss treatments and international expansion is weighing on profitability. Investors appear more concerned about the cost and timing of these investments than about the company’s revenue growth. Hims & Hers shares slide as costly weight-loss push squeezes margins
Negative Sentiment: Legal overhang: Several law firms have announced investigations into potential securities-law violations or alleged fiduciary-duty breaches. These announcements do not establish wrongdoing but add uncertainty and headline risk for shareholders. Kaplan Fox investigation announcement

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on HIMS. Truist Financial increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Friday, July 24th. Citigroup boosted their price objective on shares of Hims & Hers Health from $28.00 to $35.00 and gave the company a “neutral” rating in a research note on Thursday, July 23rd. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $26.00 price objective on shares of Hims & Hers Health in a report on Tuesday. Jefferies Financial Group set a $24.50 target price on Hims & Hers Health in a research report on Tuesday, May 12th. Finally, Bank of America lifted their target price on Hims & Hers Health from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Thursday, July 9th. Four equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $32.43.

Check Out Our Latest Stock Report on Hims & Hers Health

Hims & Hers Health Price Performance

The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The business’s fifty day simple moving average is $31.94 and its 200 day simple moving average is $26.07. The stock has a market cap of $7.18 billion, a price-to-earnings ratio of -343.16, a price-to-earnings-growth ratio of 88.90 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its earnings results on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. The business had revenue of $608.10 million for the quarter, compared to analyst estimates of $616.84 million. During the same quarter in the prior year, the business earned $0.20 earnings per share. The firm’s revenue was up 3.8% on a year-over-year basis. Research analysts predict that Hims & Hers Health, Inc. will post 0.03 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other Hims & Hers Health news, insider Irene Becklund sold 7,573 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $30.25, for a total transaction of $229,083.25. Following the completion of the sale, the insider owned 11,280 shares in the company, valued at $341,220. This trade represents a 40.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Michael Chi sold 14,027 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the sale, the chief operating officer owned 432,124 shares in the company, valued at $13,611,906. This represents a 3.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 83,126 shares of company stock valued at $2,711,339 in the last three months. 11.76% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. lifted its position in shares of Hims & Hers Health by 7.2% during the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock worth $679,456,000 after purchasing an additional 1,407,651 shares during the last quarter. Munich Reinsurance Co Stock Corp in Munich bought a new stake in Hims & Hers Health in the fourth quarter valued at about $11,187,000. Cunning Capital Partners LP bought a new stake in Hims & Hers Health in the fourth quarter valued at about $1,110,000. Virtu Financial LLC acquired a new stake in Hims & Hers Health during the fourth quarter valued at approximately $1,937,000. Finally, Norges Bank acquired a new stake in Hims & Hers Health during the fourth quarter valued at approximately $62,153,000. 63.52% of the stock is currently owned by institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.